November 2022 Vol 13, No 11
November 2022 Vol 13, No 11 | November 17, 2022
Here, we present the primary analysis of the mBCC cohort.
November 2022 Vol 13, No 11 | November 17, 2022
MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, was evaluated (vs DAN) in a pivotal phase 3 study of MF patients previously treated with a JAK inhibitor (JAKi). This subgroup analysis evaluated MOMENTUM patients with baseline platelet counts ≤150 × 109/L.
November 2022 Vol 13, No 11 | November 17, 2022
To evaluate the epidemiology of upper GI morbidity, peptic ulcer risk, and prescription GARA use among patients with MCL or CLL/SLL and provide the nursing perspective on GARA use in oncology patient care.
- 1
- 2
Page 2 of 2
Results 10 - 12 of 12
Results 10 - 12 of 12